ArticleJournal of veterinary pharmacology and therapeutics2019
A double-blind, placebo-controlled, randomized study to evaluate the weight gain drug, mirtazapine transdermal ointment, in cats with unintended weight loss.
Article in Journal of veterinary pharmacology and therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- 2026 iCatCare consensus guidelines on the diagnosis and management of chronic kidney disease in cats.Journal of feline medicine and surgery · 2026Guideline
- Owner's Perspective About the Use of Mirtazapine Transdermal Ointment in Cats-A Survey-Based Study.Animals : an open access journal from MDPI · 2025Article
- Evaluation of the Short-Term Effects of Mirtazapine on Appetite Stimulants in Dogs: A Retrospective Study and a Placebo-Controlled Trial.Animals : an open access journal from MDPI · 2025Article
- Preliminary Pharmacokinetics and Appetite Stimulant Efficacy of Oral Mirtazapine in Guinea Pigs (Animals : an open access journal from MDPI · 2025Article
- The standards of reporting trials in pets (PetSORT): Explanation and elaboration.Frontiers in veterinary science · 2023Article
- 2022 ISFM/AAFP Cat Friendly Veterinary Environment Guidelines.Journal of feline medicine and surgery · 2022Article
- Use of feeding tubes in 112 cats in an internal medicine referral service (2015-2020).Journal of feline medicine and surgery · 2022Article
- Comparison of Effects of Capromorelin and Mirtazapine on Appetite in New Zealand White Rabbits (Journal of the American Association for Laboratory Animal Science : JAALAS · 2022Article
- 2022 ISFM Consensus Guidelines on Management of the Inappetent Hospitalised Cat.Journal of feline medicine and surgery · 2022Article
- Appetite Stimulant and Anti-Emetic Effect of Mirtazapine Transdermal Ointment in Cats Affected by Lymphoma Following Chemotherapy Administration: A Multi-Centre Retrospective Study.Animals : an open access journal from MDPI · 2022Article
- ACVIM consensus statement on pancreatitis in cats.Journal of veterinary internal medicine · 2021Article
- Assessment of compounded transdermal mirtazapine as an appetite stimulant in cats with chronic kidney disease.Journal of feline medicine and surgery · 2020Article
- A double-blind, placebo-controlled, randomized study to evaluate the weight gain drug, mirtazapine transdermal ointment, in cats with unintended weight loss.Journal of veterinary pharmacology and therapeutics · 2019Article
- Evaluation of the efficacy of transdermal administration of maropitant in managing vomiting in cats.Open veterinary journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Mirtazapine is classified as a weight gain drug in cats, and the purpose of this study was to evaluate its efficacy in cats experiencing unintended weight loss. This was a multi-center, double-blind, placebo-controlled, randomized clinical study in client-owned cats ≥1 year of age, weighing ≥2 kg, with a documented loss (≥5%) in body weight. Cats were treated once daily with either 2 mg/cat mirtazapine transdermal ointment (n = 83) or placebo (n = 94) (Per Protocol population) applied to the inner surface of the pinna for 14 ± 3 days. Physical examination, body weight, complete blood count, serum chemistry, and urinalysis were performed prior to treatment and on Day 14. Changes in body weight between the mirtazapine and placebo groups were evaluated from Day 1 to Day 14 and compared using a two-sample t test. The mean percent change in body weight was +3.9% (standard deviation ±5.4%) in the mirtazapine group and +0.4% (±3.3%) in the placebo group (p < 0.0001). The most common adverse event was mild erythema at the application site in 17.4% of placebo and 10.4% of mirtazapine-treated cats. Application of mirtazapine transdermal ointment was well tolerated both topically and systemically and resulted in significant weight gain in cats experiencing unintended weight loss associated with various underlying diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.